At present, immune checkpoint inhibitor therapies, especially for PD-1/PD-L1 inhibitors [3–15, 46, 47], have been developing rapidly for NSCLC, and a large number of indicators related to the efficacy of immunotherapy and patient prognosis have also been reported [48–50]. Here, CD274 is linked to non-small cell lung carcinoma.